Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Genetics Report

The Human MC4R Promoter

Characterization and Role in Obesity

  1. Cecile Lubrano-Berthelier1,
  2. Martha Cavazos1,
  3. Catherine Le Stunff2,
  4. Kurt Haas1,
  5. Astrid Shapiro1,
  6. Sumei Zhang1,
  7. Pierre Bougneres2 and
  8. Christian Vaisse1
  1. 1Department of Medicine, Division of Endocrinology and the Diabetes Center, University of California San Francisco, San Francisco, California
  2. 2Department of Pediatric Endocrinology, Saint Vincent de Paul Hospital, University Rene Descartes, Paris, France
  1. Address correspondence and reprint requests to Dr. Christian Vaisse, Diabetes Center, University of California San Francisco, 513 Parnassus Ave., Box 0573, San Francisco, CA 94143-0573. E-mail: vaisse{at}medicine.ucsf.edu
Diabetes 2003 Dec; 52(12): 2996-3000. https://doi.org/10.2337/diabetes.52.12.2996
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Characterization and Role in Obesity

Abstract

Heterozygous mutations in the coding sequence of the serpentine melanocortin 4 receptor (MC4R) are the most frequent genetic cause of severe human obesity. Since haploinsufficiency has been proposed as a causal mechanism of obesity associated with these mutations, reduction in gene transcription caused by mutations in the transcriptionally essential regions of the MC4R promoter may also be a cause of severe obesity in humans. To test this hypothesis we defined the minimal promoter region of the human MC4R and evaluated the extent of genetic variation in this region compared with the coding region in two cohorts of severely obese subjects. 5′RACE followed by functional promoter analysis in multiple cell lines indicates that an 80-bp region is essential for the transcriptional activity of the MC4R promoter. Systematic screening of 431 obese children and adults for mutations in the coding sequence and the minimal core promoter of MC4R reveals that genetic variation in the transcriptionally essential region of the MC4R promoter is not a significant cause of severe obesity in humans.

  • 5′RACE, 5′
  • rapid amplification of cDNA ends
  • GPCR, G-protein–coupled receptor
  • MC4R, melanocortin 4 receptor
  • SNP, single nucleotide polymorphism
  • UCSF, University of California San Francisco
  • UTR, untranslated region

Obesity is a complex multifactorial disease caused by the interaction of genetic and environmental factors (1,2). Heterozygous mutations in the coding region of the melanocortin 4 receptor (MC4R) gene are the cause of 1–6% of severe early-onset obesity cases (3–10). MC4R is a seven transmembrane G-protein–coupled receptor (GPCR) encoded by a single exon gene localized on chromosome 18q22. MC4R is expressed in the paraventricular nucleus of the hypothalamus, and its activation results in the inhibition of food intake. In mice, homozygous deletion of Mc4r results in an obese phenotype (11). In humans, several recent studies reported the screening of 2,600 subjects leading to the discovery of 46 different MC4R mutations associated with obesity, most of them leading to a functional alteration of the receptor (6,7,9,10).

Theoretically, MC4R mutations in humans could cause obesity through haploinsufficiency, a dominant-negative effect, or a combination of both (12,13). Since some heterozygous human obesity–causing MC4R alleles are null or early nonsense mutations, and since heterozygous deletion of the Mc4r in mice leads to an intermediate increase in weight between wild-type mice and mice with homozygous deletion of Mc4r (11), haploinsufficiency at the MC4R locus seems sufficient to cause obesity. Under this assumption, reduced gene transcription caused by mutations in essential regions of the MC4R promoter could also be a cause of obesity in humans. The minimal promoter of the human MC4R has not been delineated, and the search for genetic variants associated with obesity at the MC4R locus has so far been limited to coding mutations.

In this study, we report the characterization of the minimal promoter of the MC4R gene and the search for sequence variants in the MC4R promoter associated with human obesity.

RESEARCH DESIGN AND METHODS

Human fetal brain RNA preparation and 5′RACE.

Transcriptional start site determination by 5′ rapid amplification of cDNA ends (5′RACE) was performed on total human fetal brain RNA using the GeneRacer kit (Invitrogen, Carlsbad, CA). First-strand cDNA was synthesized using specific primer MC4R-BR (5′ TCCACTGCAATTGAAAGCAG 3′) and avian myeloblastosis virus–reverse transcriptase. We amplified 5′ cDNA ends with MC4R-BR or MC4R-AR primer (5′ CATGGGTGAATGCAGATTCT 3′), followed by a nested PCR with MC4R-AR or MC4R-OR (5′ GCAGGAGAAGTGTGCATCCCA 3′). The PCR products were subcloned in pcDNA3.1/V5-His TOPO TA vector (Invitrogen) and analyzed by enzymatic digestion using a frequent cutter restriction enzyme (HphI) to eliminate duplicate clones. We then systematically sequenced 2 clones presenting with the same restriction map (16 clones sequenced).

Alignment of human and mouse proximal promoter.

Alignments of mouse and human 5′untranslated regions (UTRs) and regions 500 bp upstream of the main transcription start site were performed and analyzed with MacVector software (Accelrys, San Diego, CA), TRANSFAC (the Transcription Factor Database), and manual searches.

Cloning of 5′ flanking MC4R luciferase reporter vectors.

Fragments of the 5′ region of the human MC4R gene were obtained by restriction digestion of a bacterial artificial chromosome clone isolated from a human genomic bacterial artificial chromosome library (Research Genetics; Invitrogen). Fragments were ligated upstream of the Firefly luciferase gene in the plasmid pFOXLuc1 (a gift from Michael German, University of California San Francisco [UCSF]).

Cell transfection and luciferase assays.

Mouse hypothalamic GT1-7 cells were provided by Richard Weiner (UCSF). Neuro2A, HEK293, and GT1-7 cells were transfected using Effectene reagent (Qiagen, Valencia, CA), and NIH3T3 cells were transfected with Lipofectamine Reagent (Invitrogen). Cells were cotransfected with MC4R promoter constructs and a plasmid containing the Renilla luciferase to assess for transfection efficiency. Forty-eight hours after transfection, cells were harvested and Firefly and Renilla luciferases were assessed using the Stop & Glo kit (Promega, Madison, WI). Firefly luciferase activity was normalized to Renilla luciferase activity, and results were expressed relative to the result obtained with the promoterless vector.

Human subjects and phenotypes.

Two cohorts were screened for mutations in the MC4R coding sequence and minimal promoter. The first group was comprised of 266 children (aged 12.8 ± 0.8 years) from a previously described cohort (14). The protocol was approved by Cochin Ethics Committee, and informed consent was obtained from subjects and parents.

The second population was comprised of 165 unrelated, severely obese adults (BMI 40–85.3 kg/m2 [median 48.8]). This study was approved by the UCSF Committee on Human Research, and informed consent was obtained from subjects.

Mutation screening of the MC4R minimal promoter and 5′UTR.

Mutation screening was performed by direct sequencing of the coding region (9), the 5′UTR, and the minimal promoter of MC4R. This region was amplified from lymphocyte-derived genomic DNA using primers MC4R-250 (5′ GCTATAGGTACCCTTGAAAACTTAAAAAGG GA 3′) and MC4R PromRev1 (5′ GCTATACTCGAGAATTCCAGTGTCCCCC TGA 3′). Sequencing was performed on a ABI3700 automated DNA Sequencer (Applied Biosystems, Foster City, CA) and analyzed using Sequencher software (Gene Codes, Ann Arbor, MI).

RESULTS

Determination of the human MC4R transcriptional start site.

We determined transcriptional start sites of the MC4R gene from human fetal brain RNA by 5′RACE (Fig. 1). The nucleotide sequences of all the clones were colinear with the genomic sequence in the 5′ end of the coding region of human MC4R, indicating that no introns were present in the 5′UTR. Analysis of human fetal brain by 5′RACE indicates that the MC4R gene possesses two major transcriptional start sites, at 426 and 139 bp upstream of the translation initiation codon, and multiple minor transcription start sites, ranging from 213 to 366 bp (Fig. 2). We designated the transcription start site of the longest transcript as nucleotide “+1”. A TATA-like box and classical CAAT sequence (in an antisense orientation) were found at 33 and 94 bp upstream of this major transcription start site, respectively.

In silico analysis of the proximal human MC4R promoter region reveals the presence of E-boxes, cAMP response element binding protein, GATA and signal transducers and activators of transcription sites, homeoboxes, and a response element for the neural zinc finger family of transcription factors (Fig. 2).

Comparative genomic analysis of the mouse (15) and human MC4R promoter regions indicates that only the signal transducers and activators of transcription site, neural zinc finger response element, and CAAT box are conserved between species. In addition, this comparative analysis reveals the presence of a 30-bp sequence starting with the putative CAAT box that is 100% conserved between human and mouse (Fig. 2). This sequence is also present in the putative MC4R promoter of the rat and pig and is highly specific for the MC4R promoter, since BLAST analysis does not reveal the presence of another similar sequence in all four genomes. This sequence contains a potential binding site (AttGGTCA) for monomeric nuclear receptors, such as thyroid receptor or SF1 (steroidogenic factor 1). However, we did not observe any effect of SF1 on MC4R promoter activity (data not shown).

Characterization of the essential promoter region for MC4R gene transcription.

A series of progressive 5′ deletions of the human MC4R promoter, each extending to +10 bp of 5′UTR, were tested for transcriptional activity in nonneuronal cell lines (NIH 3T3 and HEK293) and in neuronal cell lines (Neuro 2A and GT-1-7) (Fig. 3). GT1-7 cells express the MC4R (16). A 2.5-kb fragment of human MC4R promoter stimulates transcription in all of the cell lines, with the highest relative level of expression in HEK 293 cells (Fig. 3). Serial deletions from 2.5 kb to −130 bp did not diminish the promoter activity in any of the cell lines (Fig. 3), while deletion of 80 additional base pairs abolished the transcriptional activity of the promoter in NIH 3T3, Neuro 2A, and GT1-7 cells and reduced it in HEK 293 cells. Therefore, we defined the presence of a minimal core promoter between −130 and −50 bp. However, this minimal promoter does not recapitulate tissue specificity because we observed a basal transcription activity in all cell lines tested. This result suggests that the regulation of the MC4R gene expression involves at least an additional repressor elsewhere in the sequence. Because they would lead to an increase in MC4R transcription, mutations in such tissue-specific repressors are unlikely to be a cause of severe obesity in humans.

Are MC4R promoter mutations implicated in human obesity?

To determine whether mutations in essential regulatory regions of the MC4R are a significant cause of severe obesity, we screened two populations of severely obese subjects for mutations in the coding region and in the minimal MC4R promoter defined above (Table 1). The frequency of MC4R mutations, other than known polymorphisms, was 3.6% (95% CI 0.78–6.49) in the adult population and 1.5% (0.04–2.97) in the child population. Both results are consistent with previous results obtained in this laboratory and with the literature. We detected three variants in the 5′UTR of MC4R. The −178 A/C single nucleotide polymorphism (SNP) was present at a frequency of 5.57% (3.4–7.73) and has been found previously at the same frequency in nonobese control populations (17). Two rare variants (A/G and G/T at 176 and 360 bp upstream of the ATG, respectively) were found in two different subjects. In contrast, no genetic variation was observed in the minimal promoter of MC4R in the 431 obese subjects of this cohort.

DISCUSSION

We have used comparative genomic tools and classical promoter studies to begin to elucidate the essential regulatory mechanisms underlying human MC4R gene expression. The major transcriptional site, according to our 5′RACE result, is located 426 bp upstream of the start of translation, where sequence analysis indicates the presence of a consensus CAP site. The DNA sequence upstream of this site contains a CAAT box (in an antisense orientation) and a nontypical TATA box. This is in contrast to the mouse Mc4r promoter that lacks a classic TATA box (15). In addition to the mouse Mc4r promoter, the 5′ flanking regions have been described for two melanocortin receptor subtypes: the human MC1R (18) and human and mouse Mc2r (19,20). Neither of these contain a TATA box nor a CAAT box. While several studies reported that most GPCR promoters are TATA-less and GC-rich (21,22), it appears that the human MC4R promoter does not share these characteristics.

Cross-species comparison reveals the presence of an identical 30-bp sequence following the putative CAAT box in the human, mouse, rat, and pig MC4R promoter. Our results confirm that this sequence is part of the minimal region that is necessary for basal MC4R promoter activity. Further characterization of trans-acting factors interacting with this cis element may lead to the discovery of novel candidate genes for human obesity.

While mutations in the MC4R gene are well established as an infrequent cause of obesity in humans (3–10), it is plausible that common SNPs in regulatory regions of MC4R could also contribute to obesity. Indeed, among multiple studies searching for linkage to obesity phenotypes, some have provided suggestive evidence of linkage between BMI (23) and body fat (24,25) on chromosome 18q21, flanking the MC4R region. These reports suggest that in addition to the rare severe obesity–causing variants in the MC4R coding region, common genetic variants/SNPs in the regulatory regions of the MC4R gene may be contributing to the risk of developing obesity, whereas in our study, the frequencies of mutations in the coding sequence of MC4R and of common genetic variants in the 5′UTR were concordant with previous reports, our results indicate that genetic variants in the essential/minimal region of the MC4R promoter are not a common monogenic cause of human obesity. Further epidemiologic studies are necessary to rule out any effect of the common SNPs found in the promoter on obesity-related phenotypes.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Determination of the human MC4R transcription start site. Lanes 1 and 3: cDNA from human embryonic brain. Lanes 2 and 4: PCR negative control. Lane 5: DNA ladder. Lanes 1 and 2: The first PCR was performed using the GeneRacer 5′ primer and MC4R-AR and the nested PCR with nested generacer 5′ primer and MC4R-OR. Lanes 3 and 4: The first PCR was performed using the GeneRacer 5′ primer and MC4R-BR and the nested PCR with nested GeneRacer 5′ primer and MC4R-AR.

FIG. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 2.

DNA sequence alignment of human and mouse MC4R promoter regions. The major transcription start sites are indicated by a “plain” arrow and defined as +1. Minor transcription start sites are indicated only for the human sequence with “open” arrows. The translation initiation codon ATG is indicated in lower case. Conserved regions between human and mouse are indicated in bold. The minimal promoter region determined in this study is indicated in italics. Potential cis-acting elements were identified using the TRANSFAC database and manual searches and are indicated as underlined. Sequences present in reverse orientation are designated with the prefix “r”.

FIG. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 3.

Transcriptional activity of the human MC4R promoter in cell lines. Promoter fragments containing sequences extending from −2,500 to −50 (5′end) to +10 bp of the major transcription site (3′end) were ligated upstream of the firefly luciferase gene and transfected into four cell lines, mouse NIH 3T3, human HEK 293, mouse Neuro 2A, and rat GT1-7. Reporter gene activity is expressed relative to the promoterless luciferase vector in the same cell type. Transfections were performed in triplicate on at least two independent occasions, and data are shown as means ± SD.

View this table:
  • View inline
  • View popup
TABLE 1

Population characteristics and genetic variations in MC4R coding sequence and 5′ flanking region

Acknowledgments

This work was supported by National Institutes of Health RO1 DK60540 and an American Diabetes Association Career Development Award (to C.V.). This study was carried out in part in the General Clinical Research Center, Moffitt/Mount Zion Hospital, UCSF, with funds provided by the National Center for Research Resources, M01 RR-00079, U.S. Public Health Service.

We thank Drs. John Kane, Raphael Merriman, James Ostroff, and Marco Patti and Karen Bagatelos, MSN, FNP, for their help in implementing the clinical study at UCSF.

Footnotes

    • Accepted August 21, 2003.
    • Received July 16, 2003.
  • DIABETES

REFERENCES

  1. ↵
    Comuzzie AG, Allison DB: The search for human obesity genes. Science 280 : 1374 –1377,1998
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Hill JO, Peters JC: Environmental contributions to the obesity epidemic. Science 280 : 1371 –1374,1998
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Vaisse C, Clement K, Guy-Grand B, Froguel P: A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20 : 113 –114,1998
    OpenUrlCrossRefPubMedWeb of Science
  4. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20 : 111 –112,1998
    OpenUrlCrossRefPubMedWeb of Science
  5. Hinney A, Schmidt A, Nottebom K, Heibult O, Becker I, Ziegler A, Gerber G, Sina M, Gorg T, Mayer H, Siegfried W, Fichter M, Remschmidt H, Hebebrand J: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 84 : 1483 –1486,1999
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Gu W, Tu Z, Kleyn PW, Kissebah A, Duprat L, Lee J, Chin W, Maruti S, Deng N, Fisher SL, Franco LS, Burn P, Yagaloff KA, Nathan J, Heymsfield S, Albu J, Pi-Sunyer FX, Allison DB: Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 48 : 635 –639,1999
    OpenUrlAbstract
  7. ↵
    Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P: Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106 : 253 –262,2000
    OpenUrlCrossRefPubMedWeb of Science
  8. Dubern B, Clement K, Pelloux V, Froguel P, Girardet J, Guy-Grand B, Tounian P: Mutational analysis of melanocortin-4 receptor, agouti-related protein, and alpha-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 139 : 204 –209,2001
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, Ferron C, Froguel P, Vaisse C: Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12 : 145 –153,2003
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348 : 1085 –1095,2003
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 : 131 –141,1997
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Ho G, MacKenzie RG: Functional characterization of mutations in melanocortin-4 receptor associated wih human obesity. J Biol Chem 274 : 35816 –35822,1999
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O’Rahilly S: Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 12 : 561 –574,2003
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Le Stunff C, Fallin D, Schork NJ, Bougneres P: The insulin gene VNTR is associated with fasting insulin levels and development of juvenile obesity. Nat Genet 26 : 444 –446,2000
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Dumont LM, Wu CS, Aschkenasi CJ, Elmquist JK, Lowell BB, Mountjoy KG: Mouse melanocortin-4 receptor gene 5′-flanking region imparts cell specific expression in vitro. Mol Cell Endocrinol 184 : 173 –185,2001
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Khong K, Kurtz SE, Sykes RL, Cone RD: Expression of functional melanocortin-4 receptor in the hypothalamic GT1–1 cell line. Neuroendocrinology 74 : 193 –201,2001
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Jacobson P, Ukkola O, Rankinen T, Snyder EE, Leon AS, Rao DC, Skinner JS, Wilmore JH, Lonn L, Cowan GS Jr, Sjostrom L, Bouchard C: Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort. J Clin Endocrinol Metab 87 : 4442 –4446,2002
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Moro O, Ideta R, Ifuku O: Characterization of the promoter region of the human melanocortin-1 receptor (MC1R) gene. Biochem Biophys Res Commun 262 : 452 –460,1999
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Naville D, Barjhoux L, Jaillard C, Lebrethon MC, Saez JM, Begeot M: Characterization of the transcription start site of the ACTH receptor gene: presence of an intronic sequence in the 5′-flanking region. Mol Cell Endocrinol 106 : 131 –135,1994
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Cammas FM, Pullinger GD, Barker S, Clark AJ: The mouse adrenocorticotropin receptor gene: cloning and characterization of its promoter and evidence for a role for the orphan nuclear receptor steroidogenic factor 1. Mol Endocrinol 11 : 867 –876,1997
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Minowa T, Minowa MT, Mouradian MM: Analysis of the promoter region of the rat D2 dopamine receptor gene. Biochemistry 31 : 8389 –8396,1992
    OpenUrlCrossRefPubMed
  22. ↵
    Zhu QS, Chen K, Shih JC: Characterization of the human 5-HT2A receptor gene promoter. J Neurosci 15 : 4885 –4895,1995
    OpenUrlAbstract
  23. ↵
    Ohman M, Oksanen L, Kaprio J, Koskenvuo M, Mustajoki P, Rissanen A, Salmi J, Kontula K, Peltonen L: Genome-wide scan of obesity in Finnish sibpairs reveals linkage to chromosome Xq24. J Clin Endocrinol Metab 85 : 3183 –3190,2000
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Chagnon YC, Chen WJ, Perusse L, Chagnon M, Nadeau A, Wilkison WO, Bouchard C: Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study. Mol Med 3 : 663 –673,1997
    OpenUrlPubMedWeb of Science
  25. ↵
    Norman RA, Tataranni PA, Pratley R, Thompson DB, Hanson RL, Prochazka M, Baier L, Ehm MG, Sakul H, Foroud T, Garvey WT, Burns D, Knowler WC, Bennett PH, Bogardus C, Ravussin E: Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians. Am J Hum Genet 62 : 659 –668,1998
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top

In this Issue

December 2003, 52(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Human MC4R Promoter
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Human MC4R Promoter
Cecile Lubrano-Berthelier, Martha Cavazos, Catherine Le Stunff, Kurt Haas, Astrid Shapiro, Sumei Zhang, Pierre Bougneres, Christian Vaisse
Diabetes Dec 2003, 52 (12) 2996-3000; DOI: 10.2337/diabetes.52.12.2996

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Human MC4R Promoter
Cecile Lubrano-Berthelier, Martha Cavazos, Catherine Le Stunff, Kurt Haas, Astrid Shapiro, Sumei Zhang, Pierre Bougneres, Christian Vaisse
Diabetes Dec 2003, 52 (12) 2996-3000; DOI: 10.2337/diabetes.52.12.2996
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes
  • Is Puberty an Accelerator of Type 1 Diabetes in IL6-174CC Females?
  • Association of the Diabetes Gene Calpain-10 With Subclinical Atherosclerosis
Show more Brief Genetics Report

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.